ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,462Medicare Part D Prescriptions Filled, Including Refills

Rank: 152 out of 617

$377K Total Retail Price of All Prescriptions

Rank: 169 out of 617

352 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
36% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 352 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

10% of this provider’s 352 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

2% of this provider’s 7,479 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 578 528 1 1
OMEPRAZOLE 389 342 2 3
SIMVASTATIN 326 298 3 2
AMLODIPINE BESYLATE 298 282 4 6
WARFARIN SODIUM 283 229 5 7
POTASSIUM CHLORIDE 264 254 6 10
FUROSEMIDE 235 223 7 4
LISINOPRIL 217 217 8 5
HYDROCHLOROTHIAZIDE 169 160 9 13
METFORMIN HCL 140 135 10 9
SERTRALINE HCL 136 132 11 20
MELOXICAM 121 110 12 24
METOPROLOL SUCCINATE 121 121 12 12
METOPROLOL TARTRATE 119 119 14 11
ALLOPURINOL 116 116 15 27
LOSARTAN POTASSIUM 114 102 16 22
GABAPENTIN 114 103 16 16
HYDROCODONE-ACETAMINOPHEN 113 88 S3 18 8
RANITIDINE HCL 111 87 19 40
SPIRONOLACTONE 94 75 20 42
ATORVASTATIN CALCIUM 89 80 21 14
ENALAPRIL MALEATE 88 73 22 34
DONEPEZIL HCL 86 86 23 30
LYRICA 82 58 24 92
GLYBURIDE 79 67 R 25 84
LANTUS 75 62 26 39
BENAZEPRIL HCL 74 62 27 44
DIGOXIN 70 53 28 48
TAMSULOSIN HCL 69 60 29 26
TRAMADOL HCL 68 66 30 15
POLYETHYLENE GLYCOL 3350 65 65 31 32
ATENOLOL 64 55 32 17
CARVEDILOL 58 53 33 19
LACTULOSE 55 52 34 179
LIPITOR 54 46 35 118
CRESTOR 52 47 36 28
CITALOPRAM HBR 51 51 37 18
CLOPIDOGREL 50 47 38 53
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.